Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 9Observational 2Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 34Multiple Myeloma 32Recurrence 29Prostatic Neoplasms 28Melanoma 21Leukemia, Myeloid, Acute 21Breast Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Glioblastoma 15Pancreatic Neoplasms 14Sarcoma 13Neuroblastoma 13Lymphoma 13Glioma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Colorectal Neoplasms 10Ovarian Neoplasms 9Lung Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Lymphoma, Large B-Cell, Diffuse 8Lambert-Eaton Myasthenic Syndrome 8Pheochromocytoma 7Neuroendocrine Tumors 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Gastrointestinal Stromal Tumors 7Carcinoma, Renal Cell 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Pancreatic Ductal Adenocarcinoma (PDAC) × Clear all
NCT07612930 2026-05-29

Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy

Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.

Available
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡